Study of EVO756 in Adults With Migraine
ConditionMigraine
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-64
SponsorEvommune, Inc.
About this trial
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
Eligibility criteria
Qualifiers
Adults aged 18 to <65 years
Migraine with or without aura, per ICHD-3 criteria
History of failure with prior preventive migraine treatments
Not currently using migraine preventive therapy
Disqualifiers
Difficulty distinguishing migraine from other headache types or presence of other primary headache disorders
Use of certain medications
Any clinically significant medical, psychiatric, neurological, cardiovascular, or laboratory abnormalities
Trial design
Treatments tested in this trial
- EVO756, Dose 1
- EVO756, Dose 2
- Placebo
Treatment groups
330 Participants
are divided into 3 treatment groupsLocations
14California
CA Medical Clinic for Headache90067, Los Angeles United States
Connecticut
New England Institute for Neurology and Headache06905, Stamford United States
Florida
Clinical Neuroscience Solutions, Inc.32256, Jacksonville United States
Apple Medical Research Group, Inc331216, Miami United States
Sponsors and collaborators
Evommune, Inc.
Lead sponsor
Source ClinicalTrials.gov